

KFSHRC and Kopra Bio Sign MoU to Accelerate Viral-Vector Oncology and Launch Glioblastoma Program in Saudi Arabia

RIYADH, SAUDI ARABIA, October 30, 2025 /EINPresswire.com/ -- King Faisal Specialist Hospital and Research Centre (KFSHRC) and Kopra Bio, Inc. have signed a memorandum of understanding to explore a strategic collaboration advancing genetically engineered viral-vector therapeutics for solid tumors. The collaboration begins with KB-516, Kopra Bio's lead candidate, a replicating retrovirus that delivers an IL-15 super-agonist to convert immunologically "cold" tumors into "hot" immunogenic environments.



The signing took place at KFSHRC's pavilion during the Global Health Exhibition 2025, with signatories: Dr. Majid Alfayyadh, Chief Executive Officer, King Faisal Specialist Hospital and Research Centre; and Dr. Andrew Bartynski, Chief Executive Officer, Kopra Bio, Inc.

The MoU highlights the intent to explore a value-based partnership model that includes in-kind contributions from KFSHRC in exchange for equity participation at Kopra Bio. It also establishes a framework to progress IND-enabling studies, scale clinical-grade vector manufacturing, conduct regulatory submissions to the U.S. FDA and the Saudi FDA, and initiate a Phase 1/2a clinical trial in recurrent glioblastoma patients in the Kingdom, while laying the groundwork for technology transfer and capacity building in Saudi Arabia.

The three-year MOU provides a non-exclusive framework to translate next-generation oncology platforms from concept to clinic through coordinated scientific exchange, local skills development, and high-quality clinical execution across KFSHRC's Centers of Excellence.

KFSHRC has been ranked first in the Middle East and North Africa and fifteenth globally among the world's top 250 academic medical centers for 2025 and recognized by Brand Finance as the

region's most valuable healthcare brand. It is also listed among Newsweek's World's Best Hospitals 2025, Best Smart Hospitals 2026, and Best Specialized Hospitals 2026, reaffirming its leadership in innovation-driven care.

About Kopra Bio

Kopra Bio is a U.S.-based biotechnology company pioneering genetically engineered viral vectors that transform the treatment of solid tumors. Its lead program, KB-516, is a replicating retrovirus delivering an IL-15 super-agonist designed to convert non-immunogenic cancers into immune-responsive ones. The company's platform integrates synthetic biology, immuno-oncology, and translational research to accelerate the next generation of in vivo cancer gene therapies.

Riyadh

King Faisal Specialist Hospital and Research Centre

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/862898531>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.